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RESUMEN
Introducción: La hipertrofia concéntrica del ventrículo izquierdo (HVI) es un riesgo cardiovascular independiente para eventos como 
muerte súbita cardiaca, infarto del miocardio y enfermedad cerebrovascular. El objetivo de este estudio fue determinar la especificidad, 
sensibilidad, valor predictivo positivo (VPP) valor predictivo negativo (VPN) y exactitud de Tc-99 – SPECT sincronizado al ECG, para la 
detección de HVI. 
Métodos: Pacientes enviados por presencia o sospecha de enfermedad coronaria  que fueron sometidos a estudio con Tc-99–SPECT y 
que contaran con un ecocardiograma (ECO) realizado dentro de los dos meses previos al estudio fueron prospectivamente incluidos en 
el estudio. El grupo consistió de 52 pacientes, 25 hombres, con una edad media de 64.5 ± 12 años. 
Resultados: Cuando la HVI fue definida por ECO como un grosor medio de la pared septal anterior en diástole + pared  posterior del VI 
en diástole /2 >   11 MM, el SPECT tuvo una sensibilidad y especificidad de  91% y 33% respectivamente,  con un VPP de 94%& y VPN 
de 48% y exactitud de 58%. Cuando la HVI fue definida como una relación grosor/radio del ventrículo izquierdo (h/r) > 0.45, el método 
mostró una especificidad de 95%, sensibilidad de 37% y VPP de 97% y VPN de 54% con exactitud de 62%. En hombres, cuando los 
criterios para HVI fueron una masa de> 11 g/m2, la especificidad y sensibilidad para el método fueron de 100% y 20% con VPP, VPN y 
exactitud de 100%, 45%  y 48%, respectivamente. En mujeres, cuando la HVI fue definida como una masa > 106 g/m2, el SPECT tuvo una 
especificidad de 91% y sensibilidad de 44%, VPP de  94% y VPN y exactitud de 42% y 63%. Si el criterio para HVI fue de masa  >125 g/
m2, el SPECT tuvo especificidad y sensibilidad de 86% y 30% respectivamente,  y un VPP de 85%, VPN de 64% con exactitud de 62%. 
Palabras clave: ventrículo izquierdo, hipertrofia, Tc-99 tetrofosmin.
ABSTRACT
Introduction. Left ventricular hypertrophy (LVH) is a strong cardiovascular risk factor and an independent major cardiac risk factor for 
sudden cardiac death, myocardial infarction and stroke. The objective of this study was to determine the specificity, sensitivity, positive 
predictive value (PPV) Negative Predictive Value (NPV) and accuracy of a Tc-99 gated-SPECT method for detecting LVH. 
Methods: Patients referred for evaluation of known or suspected CAD, who underwent myocardial perfusion SPECT imaging with Tc-99 
Tetrofosmin and who had also an echocardiogram performed within the previous 2 months were prospectively enrolled in the study.  The 
group consisted of 52 patients, 25 men and 27 women, the mean age was 64.5 ± 12 yrs. 
Results: When the echocardiographic LVH was defined as a mean wall thickness VSTd + PWTd/2 ≥ 11mm, the SPECT method had a 
specificity and sensitivity of 91% and 33% respectively, a PPV of 94%, a NPV of 48% and an accuracy of 58%. When the LVH  was defined 
as a thickness to radius ratio (h/r) >0.45, the SPECT Method showed a specificity of 95%, sensitivity of 37% and a PPV of 97% and NPV 
of 54% with an accuracy of 62% . In Men, when the LVH criteria was a LV Mass >111 g/m2, the specificity and sensitivity for the SPECT 
method criteria was 100% and 20% respectively with a PPV, NPV and Accuracy of 100%, 45% and 48%. In Women, when LVH was defined 
as a LV Mass >106 g/m2, the SPECT method had a specificity of 91% and sensitivity of 44%, a PPV of 94%, and NPV and Accuracy of 
42% and 63%. If the criteria was a LV Mass >125 g/m2, SPECT showed a specificity and sensitivity of 86% and 30% respectively and a 
PPV of 85% and a NPV of 64% with an Accuracy of 62 %.
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Left ventricular hypertrophy (LVH) is the result of the left ventricle’s adaptation to chronic pressure overload, volume overload, endocrine processes1 or a specific myocardial disease. In the general 
population, hypertension is the most common cause of LVH, 
which was recognized as a strong cardiovascular risk fac-
tor early in the Framingham study.2 In that study, LVH was 
determined by electrocardiographic (ECG) criteria, and was 
found to be associated with increased overall mortality rates. 
LVH is also an independent major cardiac risk factor for 
sudden cardiac death, myocardial infarction and stroke.3-4 
The presence of coronary heart disease (CHD) or congestive 
heart failure might be aggravated by LVH.1 
Several ECG criteria in addition to the Framingham 
criteria are in clinical use, and the ECG has been suggested 
as a valuable tool for detecting LVH at a lower cost when 
compared to echocardiography, which is a direct assess-
ment of LV wall thickness and cavity dimensions, but it 
is only recommended for a subset of patients as an initial 
screening tool.5,6 
Left ventricular hypertrophy is not always pathological; 
it is common in healthy athletes. Additional data might be 
necessary to distinguish between a pathological and a non 
pathological LVH.7 Echocardiography is the most common 
way to obtain such information.2,8 
It is common in myocardial perfusion studies to observe 
patients where the myocardial walls appear thick and the 
left ventricular cavity small, raising the question whether 
such patients could have LVH, an important additional 
observation given the above prognostic implications. The 
objective of this study was to determine the ability of a new 
Tc-99 gated-SPECT method to detect LVH, and compare 
the method’s diagnostic performance with the clinically 
used ECG criteria for LVH, using common echocardio-
graphic criteria as the reference.
PATIENTS AND METHODS
Patient population
Pilot group
Patients referred for evaluation of known or suspected 
CAD, who underwent myocardial perfusion SPECT 
imaging with Tc-99 Tetrofosmin, and who had also an 
echocardiogram performed within 2 months were pro-
spectively enrolled in the study. Patients were excluded if 
gated-SPECT could not be performed, if disproportionate 
septal hypertrophy existed, if the patient had large perfu-
sion defects in the rest scan (i.e. more than 40 percent 
decreased tracer uptake in a myocardial wall when com-
pared with the best perfused wall). The group consisted 
of 52 patients, 25 men and 27 women, the mean age was 
64.6 ±12 yr. (Table 1)
 
Echocardiographic measurements
All the patients underwent echocardiographic study within 
2 months of their perfusion imaging study. Two-dimen-
sionally guided LV M-mode recordings were obtained 
using a commercially available echocardiograph with a 
2.5 MHz transducer, according to the recommendations 
of Devereux et al.9 For each measurement and tracing, a 
minimum of three cardiac cycles was used. M-mode left 
ventricular chamber dimensions were measured from 
parasternal long-axis views according to specifications 
of the American Society of Echocardiography.10 The mea-
surements included LV internal diameter at end-diastole 
(LVIDd), end-systole, the ventricular septal thickness at 
end-diastole (VSTd), and the posterior wall thickness at 
end-diastole (PWTd). Diastolic measurements were used 
to calculate the VSTd/PWTd ratio, and LV mass, accord-
ing to Devereux:11
Table 1. Demographic data of the patients 
Male Female Total p
Sex (n) 25 27 52 NS
Age (years) 64 ± 12 55 ± 9 64.6 ± 12 NS
BSA (g/m2) 1.99 ± 0.3 1.81 ± 0.1 1.90 ± 0.3 < 0.01
Systolic BP 
(mm/Hg)
136 ± 13 143 ± 25 139 ± 20 NS
Diastolic 
BP
82 ± 9 81 ± 11 82 ± 10 NS
Echo EDD 
(mm)
54 ± 9 46 ± 6 50 ± 8 0.01
Echo ESD 
(mm)
40 ± 10 30 ± 5 35 ± 9 0.001
Echo EF% 52 ± 11 57 ± 12 54 ± 12 NS
Nuclear 
EF%
49 ± 12 59 ± 16 54 ± 15 0.02
ESV (mL) 67 ± 32 35 ± 26 50.7 ± 33 0.001
EDV 128 ± 42 77 ± 30 101.3 ± 44 < 0.001
SV 61 ± 19 41 ± 11 51 ± 18 < 0.001
LV Mass 
(g/m2)
131 ± 49 117 ± 48 123 ± 49 NS
Echo 
thickness 
(mm)
11.6 ± 1.9 11.7 ± 3 11.7 ± 2.2 NS
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0.80 x {1.04 x [(septal thickness + LV internal diameter 
+ posterior wall thickness) 3 - (LV internal diameter) 3]} + 
0.6 g and normalized by body surface area.
Definition of LVH
a) a mean left ventricle wall thickness (IVSTd+PWTd 
/2) of > 11 mm; 
b) a thickness to LV cavity radius ratio ≥ 0.45 (half of 
the LVIDd divided by the LV mean diastolic wall 
thickness in mm),12 (reference)
c) LV Mass indexed by body weight >106 g/m2 in 
women and >111 g/m2 in men 
d) Overall LV mass indexed by body weight >125 g/
m2. 
Myocardial perfusion imaging
A stress-rest imaging protocol was used. Eight mCi Tc-
99m Tetrofosmin was administered at peak stress (defined 
as maximal possible effort, moderately severe chest pain, 
dyspnea or fatigue) and the test continued for 30-60 sec-
onds. Stress imaging was performed 20-40 min post tracer 
administration. Two to 3 hours later 24 mCi Tc-99m Tet-
rofosmin was injected rest. Rest imaging was performed 
20-40 min post tracer administration. 
A 3-headed gamma-camera (Prism, Picker Int., Cleve-
land Ohio) equipped with high resolution collimators was 
used. Data were acquired in 64x 64 matrix, over 180° from 
LPO 45 to RAO 45, 32 angles, 25 sec/angle for the stress 
study, and 20 sec/angle for the rest study. All studies were 
reconstructed using filtered back projection (ramp). A low 
pass filter was applied (order 0.5 with cutoff 0.33 for rest 
studies and order 0.5 with cutoff 0.25 for stress studies). 
The data were reformatted to vertical long, short and 
horizontal long axis (6 mm) according to the individually 
determined anatomical cardiac long axis. Software zoom 
was applied for display and visual assessment purposes, 
and coronal slices were added hereby generating perfusion 
images representing regional myocardial perfusion in the 
basal, mid and apical thirds of the myocardium. Midven-
tricular sagittal and transaxial slices were also created for 
visualization of the apex and the walls in longitudinally 
context. The stress and rest studies were carefully aligned 
to insure that the myocardial segments in both studies was 
compared. The two studies were displayed simultaneously 
on a high resolution monitor using a standard color table 
for visual semiquantitative analysis. 
The rest SPECT acquisition was acquired on a gated 
study divided into 8 frames with an acceptance window 
of ± 10% around the mean R-R interval during 1 minute 
prior to the study.
Left ventricular size evaluation
A short axis mid-ventricular slice, approximate at the level 
of insertion of the papillary muscles was selected and a 
pixel area from the external and internal borders was ob-
tained (Figure 1). Two methods were used: The ratio of 
the external area divided by the internal cavity area was 
defined as SPECT method. 
Using a ROC curve analysis we obtained a SPECT 
threshold for abnormality of an external to internal pixel 
area ratio ≥ 16.
ECG measurements
A 12-lead ECG was recorded prior to the stress test in all 
subjects at a 25mm/second and 1mV/cm calibration. The 
patient was considered as having LVH by ECG when any 
of the following criteria were met: 
a)  Sokolow-Lyon13 (sum of the amplitudes of the S 
wave in lead V1 and the R wave in V5 and V6 >35 
mm). 
b)  Gender-specific Cornell voltage criteria14 (SV3 + R 
aVL > 28 mm in men and >20 mm in women).
c)  Framingham Criteria15 (coexistence of a definite 
strain pattern and at least one of the following: 
sum of the amplitudes of the S wave in lead III and 
the R wave on lead I >25 mm, sum of the S wave 
Figure 1. 
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amplitude in V1 or V2 and the amplitude of the R 
wave in V5 or V6 >35 mm, S wave in V1 or R in V6 
>25mm.
RESULTS
Prevalence of LVH
The prevalence of LVH in the pilot group according to the 
4 different echocardiographic LVH criteria ranged from 
44% to 60% (Table 2). 
Electrocardiographic Framingham criteria evidence of 
LVH was found overall in 7% to 24% of the population 
studied (Table 3). LVH by Sokolow criteria was found in 
4% to 20% of the patients, and LVH by Cornell criteria 
was found in 7% to 20%. 
The SPECT-1 method showed a prevalence of LVH of 
12% to 21% of the cases.
SPECT method performance
When the echocardiographic LVH was defined as a mean 
wall thickness VSTd + PWTd/2 ≥ 11mm, the SPECT method 
(≥16) showed a specificity and sensitivity of 91% and 33% 
respectively, a PPV of 94%, a NPV of 48% and an accuracy 
of 58% (Table 4). When the LVH criteria used was a thickness 
to radius ratio >0.45, the SPECT method showed a specificity 
and sensitivity of 95% and 37% respectively and a PPV of 
97%, a NPV of 54% and an accuracy of 62% (Table 3).
If the echocardiographic diagnosis of LVH was de-
fined as follows: In men, the LVH echocardiographic 
criteria of LV mass >111 g/m2 allowed a specificity and 
sensitivity for the SPECT method criteria 100% and 
20% respectively with a PPV, NPV and accuracy of 
100%, 45% and 48% respectively (Table 5).
In women, when LVH was defined as a LV mass >106 
g/m2, the SPECT method had a specificity of 91% and the 
Table 2. Prevalence of LVH according to he different echocardiographic thresholds
Echo T/R > 0.45 Echo > 11 LV mass >  
106g/m2(F)
LV mass >
111g/m2(M)
LV mass >
125g/m2
Framingham 13.46% 13.46% 7.41% 24% 9.62%
Sokolow 9.62% 9.62% 3.70% 20% 8%
Cornell 11.5% 13.46% 7.41% 20% 11.54%
SPECT 1  (≥16) 21.15% 19.23% 25.93% 12% 13.46%
SPECT 1: External area in pixels divided by internal area in pixels.
Table 3. Diagnostic performance of common ECG criteria and SPECT in 52 patients
Sensitivity
(SENS)
Specificity
(SPEC)
Positive predictive
value 
Negative predictive
value 
Accuracy
Framingham 23% 91% 94% 49% 52%
Sokolow 17% 91% 94% 47% 48%
Cornell 20% 91% 94% 48% 50%
SPECT 1 (≥ 16) 37% 95% 97% 54% 62%
SPECT 1: External area in pixels divided by internal area in pixels.
Table 4. Comparison of diagnostic performance of common ECG criteria for LVH, criteria in 52 patients
Sensitivity
(SENS)
Specificity
(SPEC)
Positive predictive
value 
Negative predictive
value 
Accuracy
Framingham 23% 91% 94% 49% 52%
Sokolow 17% 91% 94% 47% 48%
Cornell 23% 95% 97% 49% 54%
SPECT 1
(≥ 16)
33% 91% 94% 48% 58%
SPECT 1: External area in pixels divided by internal area in pixels.
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Table 5. Diagnostic performance of common ECG criteria and SPECT (n = 52)
Sensitivity Specificity Positive predictive
value 
Negative predictive
value 
Accuracy
Framingham 40% 100% 100% 53% 64%
Sokolow 33% 100% 100% 44% 60%
Cornell 33% 100% 100% 50% 60%
SPECT 1 (≥ 16) 20% 100% 100% 45% 48%
SPECT 1: External area in pixels divided by internal area in pixels.
Table 6. Diagnostic performance of common ECG criteria and SPECT (n = 52)
Sensitivity
(SENS)
Specificity
(SPEC)
Positive predictive
value 
Negative predictive
value 
Accuracy
Framingham 12% 91% 94% 44% 44%
Sokolow 6% 91% 94% 42% 41%
Cornell 12% 91% 94% 44% 44%
SPECT (≥ 16) 44% 91% 94% 55% 63%
SPECT 1: External area in pixels divided by internal area in pixels.
highest sensitivity (44%), when compared to the different 
ECG criteria. There was no difference in the PPV of 94%, 
but there was a higher NPV and accuracy (42% and 63%) 
with that of the ECG criteria (Table 6). When the criteria 
for LVH was a LV mass >125 g/m2, the SPECT 1 method 
(≥16) showed a specificity and sensitivity of 86% and 30% 
respectively and a PPV of 85% and a NPV of 64% with 
an accuracy of 62% (Table 7).
Electrocardiographic performance
When LVH was defined as a mean wall thickness VSTd/
PWTd ≥ 11mm, we found a specificity and sensitivity of 
91% and 23% respectively for the Framingham criteria, 
with a PPV of 94% and a NPV of 47% and an accuracy of 
52%. The Sokolow criteria had a specificity and sensitivity 
of 91% and 17%, with both PPV and NPV of 91% and 
47% and an accuracy of 48%. The Cornell criteria showed 
a specificity and sensitivity of 95% and 23%, with a PPV, 
NPV and accuracy of 94%, 48% and 54% respectively 
(Table 4).
In men, when the criteria for LVH was a left ventricu-
lar mass >111g/m2, the specificity and sensitivity for the 
ECG LVH criteria was 100% and 40% respectively for 
the Framingham criteria, a PPV and NPV of 100% and 
53% respectively and an accuracy of 64%. The Sokolow 
criteria had a specificity and sensitivity of 100% and 33% 
with a PPV of 100% and a NPV of 40% and accuracy of 
60%. The Cornell criteria showed a specificity of 100% 
and a sensitivity of 33%, with a PPV, NPV and accuracy 
of 100%, 50% and 60% respectively (table 5).
LVH defined as a left ventricular mass >106 g/m2 in 
Women, Framingham criteria showed a specificity and 
sensitivity of 91% and 12% respectively, a PPV and NPV 
of 94% and 44% and an accuracy of 44%. Sokolow cri-
teria showed a specificity and sensitivity of 91% and 6% 
and a PPV of 94%, NPV of 42% and an accuracy of 41%. 
The Cornell criteria showed a specificity of 91% and a 
sensitivity of 12%, with PPV and NPV of 92% and 63% 
respectively and an accuracy of 44% (Table 6).
When the threshold for LVH was defined as: LV mass 
>125 g/m2, the specificity and sensitivity for the ECG LVH 
criteria was 86% and 22% respectively for the Framingham 
criteria, a PPV and NPV of 85% and 62% respectively. 
The Sokolow criteria had a specificity and sensitivity of 
90% and 17% with a PPV of 88% and a NPV of 60%. 
The Cornell criteria showed a specificity of 93% and a 
sensitivity of 26%, with a PPV, a NPV of 92% and 63% 
respectively an accuracy of 62% (Table 7).
If LVH was defined as a thickness to radius ratio ≥ 0.45, 
the specificity and sensitivity for the ECG LVH criteria 
in our population was 91% and 23% respectively for the 
Framingham criteria, a PPV, NPV and accuracy of 94%, 
49% and 52% respectively. The Sokolow showed specific-
ity and sensitivity of 91% and 17% with a PPV of 94% and 
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a NPV of 47% .The accuracy for this ECG method was 
48%. The Cornell criteria had a specificity of 91% and a 
sensitivity of 20%, with a PPV and NPV of 94% and 48% 
respectively and accuracy of 50% (table 3).
Validation phase 
Fifty patients were studied several weeks after the initial 
patient population was evaluated. The group consisted of 
25 women and 25 men with an echocardiogram performed 
within < 2 months of the cardiac SPECT study. The patients 
did not have any perfusion abnormality at rest and were 
randomly chosen. A short axis slice at the approximate 
level of insertion of the papillary muscles was selected 
and a pixel area from the external and internal borders 
was obtained (Figure 1). The ratio of the external pixels 
divided by the internal cavity pixels (SPECT method) was 
used and a value ≥ 16 was defined as abnormal.
Twenty-one patients had echocardiographic signs of 
LVH (echo thickness ≥11 mm). The specificity of the 
SPECT method (ratio ≥ 16) was 82%, sensitivity 46%, 
predictive positive value 76% and negative predictive 
value of 56%.
DISCUSSION
Left ventricular hypertrophy is a strong independent 
predictor of adverse cardiovascular events, therefore, 
identification of those patients with LVH is critical to de-
termine their therapeutic approach, since the regression of 
hypertrophy ensues a decrease in the risk of future events.16 
One of the most common methods to detect this subgroup 
of patients is electrocardiography, and several studies sup-
port its prognostic value, very low sensitivity, with a good 
specificity. Several factors interfere with the value of ECG 
to detect LVH and include the different criteria employed, 
sex, smoking, and obesity among others.17 
Table 7. Diagnostic performance of common ECG criteria and SPECT (n = 52)
Sensitivity Specificity Positive predictive
value 
Negative redictive
value 
Accuracy
Framingham 22% 86% 85% 62% 58%
Sokolow 17% 90% 88% 60% 58%
Cornell 26% 93% 92% 63% 63%
SPECT 1 (≥ 16) 30% 86% 85% 64% 62%
SPECT 1: External area in pixels divided by internal area in pixels.
Previous studies have shown a good correlation with 
LV size and volume determination with Tl-201,18 to our 
knowledge, this is the first attempt to determine the pres-
ence of LVH with this method. Hypertension is commonly 
associated with coronary artery disease and LVH, and myo-
cardial perfusion imaging with Tc-99 provides valuable 
information, which includes perfusion and left ventricular 
function. The value of adding such information, such as 
LVH is yet to be studied. 
In our study, SPECT detection of left ventricular hyper-
trophy showed a similar specificity and a better sensitivity 
when compared to ECG criteria. The definition for LVH 
varies according to different authors, therefore, the results 
obtained in this analysis varies according to the echocar-
diographic definition of LVH. Other variables that suggest 
LVH include the visual appearance of thick ventricular walls 
and small cavity, the presence of a high tracer uptake by the 
papillary muscles and left ventricular apical thinning were 
very inconsistent in our population. One of the advantages 
of our method is that it can detect LVH even in the presence 
of cavity dilatation, as shown in table 3. 
LIMITATIONS OF THE STUDY
This method has proven to be less sensitive and specific 
in the detection of left ventricular hypertrophy by direct 
measurements and by determination of pixel areas when 
compared to echocardiography which has been widely 
validated as a method accurate in detecting LVH. SPECT 
images provide an inaccurate definition of the endocar-
dial and epicardial borders due to partial volume effect 
and scattering, especially in small hearts and in women. 
Processing tools such as filters that help decrease such 
technical limitations will help clear out the value of this 
methods to identify patients with left ventricular hyper-
trophy.
De la Peña Almaguer E et al.
35Volumen 11, Núm. 42, enero-marzo, 2009
Detection of left ventricular hypertrophy by Tc-99 tetrofosmin gated-SPECT
REFERENCES
1. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in 
hypertension. N Engl J Med 1992;327:998-1008.
2. Savage DD, Garrison RJ, Kannel WB et al. The spectrum of 
left ventricular hypertrophy in a general population sample: 
the Framingham study. Circulation 1987;75(Suppl.:I26-I33).
3. Koren, Devereux RB, Casale PN, et al. Relation of of left 
ventricular mass and geometry to morbidity and mortal-
ity in uncomplicated essential hypertension. Ann Int Med 
1991;114:345-52.
4. Liao Y, Cooper RS, McGee DL, et al. The relative effects 
of left ventricular hypertrophy, coronary artery disease, and 
ventricular dysfunction on survival among black adults. JAMA 
1995;273:1592-7.
5. The sixth report of the Joint National Committee on Detec-
tion, Evaluation, and Treatment of High Blood Pressure. Arch 
Intern Med 1997;157:2413-46. [Erratum, Arch Intern Med. 
1998;158:573.]
6. Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel 
WB. Prognostic implications of baseline electrocardiographic 
features and their serial changes in subjects with left ventricular 
hypertrophy. Circulation 1994;90:1786-93.
7. Spirito P, Pellicia A, Proschan MA, et al. Morphology of the 
“athlete’s heart” assessed by echocardiography in 947 elite 
athletes representing 27 sports. Am J Cardiol 1994;74:802-
6.
8. Devereux RB, Roman, MJ, Ganau A, et al. Cardiac and arterial 
hypertrophy and atherosclerosis in hypertension. Hypertension 
1994,23(part 1):802.
9. Devereux RB, Liebson PR, Horan MJ. Recommendations 
concerning the use of echocardiography in hypertension and 
general population research. Hypertension 1987;9(Suppl II):II-
97-II-104.
10. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux 
R, Feigenbaum H, et al. Recommendations for quantitation 
of the left ventricle by two-dimensional echocardiography. 
American Society of Echocardiography Committee on Stan-
dards, Subcommittee on Quantitation of Two-Dimensional 
Echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
11. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, 
Sachs I, Reichek N. Echocardiographic assessment of left 
ventricular hypertrophy: comparison to necropsy findings. Am 
J Cardiol 1986;57:450-8.
12. Grossman W, Jones D, McLaurin LP. Wall stress and pat-
terns of hypertrophy in the human left ventricle. J Clin Invest 
1975:56:56-64.
13. Sokolow M, Lyon TP. The ventricular complex in left ventricular 
hypertrophy as obtained by unipolar precordial and limb leads. 
Am Heart J 1949;37:161-86.
14. Casale P, Devereux RB, Kligfield P, et al. Electrocardiographic 
detection of left ventricular hypertrophy: development and 
prospective validation of improved criteria. J Am Coll Cardiol 
1985;6:572-80.
15. Levy D, Labib SB, Anderson KM, et al. Determinants of sen-
sitivity and specificity of electrocardiographic criteria for left 
ventricular hypertrophy. Circulation 1990;81:815-20.
16. Devereux RB, Agabiti-Rosei E, Dahlof B, et al. Regression 
of left ventricular hypertrophy as a surrogate end-point for 
morbid events in hypertension treatment trials. J Hypertens 
1996;14(Suppl. 2): S95-S102.
17. Levy D, Labib SB, Anderson KM, et al. Determinants of sen-
sitivity and specificity of electrocardiographic criteria for left 
ventricular hypertrophy. Circulation 1990;81:815.
18. Kurata C, Wakabayashi Y, Shouda S, Mikami T, Tawarahara 
K. Quantification of left ventricular size on exercise thalli-
um-201 single-photon emission tomography. Eur J Nucl Med 
1996;23:762-7.
